Bruker stock kpis
Want to see BRKR full AI Analyst Report?
Operating Income by Segment
Bruker reported operating income by segment of -$218.60M in Q3 2026. The highest value was $131.30M in Q3 2022.
Shows profit contribution from each business unit, revealing which segments deliver healthy margins and which are weighing on earnings. Helps identify whether revenue growth is translating into sustainable profitability and where management is focusing cost control or investment efforts.
BSI Life Science’s operating income effectively disappears after 2022 because management reclassified businesses in the July 2026 reorg (Biosystems/Nano/BMID/BEST), not necessarily because core profitability vanished; BioSpin and CALID show steady, seasonally stronger profitability while Nano is more volatile but recovering. A big swing in Unallocated Expenses reflects the $135M goodwill impairment and other central charges, so GAAP profits are depressed even as non‑GAAP margins improve from realized cost savings—watch deep‑tech order lead times for delayed revenue conversion and Q4 upside.
BRKR Operating Income by Segment
| Period | Unallocated Expenses | Corporate & Other | BSI BioSpin | BSI CALID | BSI Life Science | BSI NANO | BEST | Total |
|---|---|---|---|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | -$233.70M | -$28.70M | $0.00 | $0.00 | $0.00 | $31.70M | $12.10M | -$218.60M |
| Q2 2026Jun 30, 2026 | -$183.90M | -$32.80M | $41.70M | $72.30M | $0.00 | $29.80M | $7.60M | -$65.30M |
| Q1 2026Mar 31, 2026 | -$74.10M | -$29.10M | $28.80M | $62.60M | $0.00 | $14.40M | $7.60M | $10.20M |
| Q4 2025Dec 31, 2025 | -$77.20M | -$31.90M | $63.00M | $71.80M | $0.00 | $45.10M | $5.50M | $76.30M |
| Q3 2025Sep 30, 2025 | -$157.60M | -$34.00M | $33.30M | $76.00M | $0.00 | $23.50M | $7.00M | -$51.80M |
| Q2 2025Jun 30, 2025 | -$60.00M | -$21.10M | $23.10M | $53.30M | $0.00 | $9.40M | $7.20M | $11.90M |
| Q1 2025Mar 31, 2025 | -$70.00M | -$26.90M | $37.10M | $61.50M | $0.00 | $23.10M | $7.00M | $31.80M |
| Q4 2024Dec 31, 2024 | -$105.70M | -$31.70M | $78.60M | $78.00M | $0.00 | $44.30M | $8.60M | $72.10M |
| Q3 2024Sep 30, 2024 | -$61.00M | -$24.70M | $56.80M | $58.70M | $0.00 | $30.60M | $7.70M | $68.10M |
| Q2 2024Jun 30, 2024 | -$62.40M | -$24.30M | $46.60M | $58.40M | $0.00 | $19.20M | $10.60M | $48.10M |
| Q1 2024Mar 31, 2024 | -$35.80M | -$23.10M | $34.60M | $51.10M | $0.00 | $29.80M | $8.20M | $64.80M |
| Q4 2023Dec 31, 2023 | $0.00 | -$40.00M | $72.20M | $57.70M | $0.00 | $9.40M | $4.20M | $103.50M |
| Q3 2023Sep 30, 2023 | $0.00 | -$26.00M | $52.50M | $50.00M | $0.00 | $39.00M | $9.00M | $124.50M |
| Q2 2023Jun 30, 2023 | $0.00 | -$24.00M | $23.80M | $44.00M | $0.00 | $31.30M | $11.10M | $86.20M |
| Q1 2023Mar 31, 2023 | $0.00 | -$19.70M | $47.40M | $57.60M | $0.00 | $29.40M | $8.00M | $122.70M |
| Q4 2022Dec 31, 2022 | $0.00 | -$22.50M | $0.00 | $0.00 | $102.80M | $40.80M | $9.90M | $131.00M |
| Q3 2022Sep 30, 2022 | $0.00 | -$16.40M | $0.00 | $0.00 | $104.20M | $35.30M | $8.20M | $131.30M |
| Q2 2022Jun 30, 2022 | $0.00 | -$17.50M | $0.00 | $0.00 | $70.20M | $14.60M | $6.60M | $73.90M |
| Q1 2022Mar 31, 2022 | $0.00 | -$18.30M | $0.00 | $0.00 | $85.90M | $22.30M | $6.60M | $96.50M |
| Q4 2021Dec 31, 2021 | $0.00 | -$18.80M | $0.00 | $0.00 | $122.00M | $18.30M | $3.90M | $125.40M |
| Q3 2021Sep 30, 2021 | $0.00 | -$16.90M | $0.00 | $0.00 | $100.90M | $21.80M | $7.40M | $113.20M |
| Q2 2021Jun 30, 2021 | $0.00 | -$15.80M | $0.00 | $0.00 | $73.60M | $21.00M | $6.80M | $85.60M |
| Q1 2021Mar 31, 2021 | $0.00 | -$16.20M | $0.00 | $0.00 | $88.90M | $12.30M | $4.10M | $89.10M |

